Compounds > vancomycin
Page last updated: 2024-08-21

vancomycin and rifaximin

vancomycin has been researched along with rifaximin in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Galang, MA; Gerding, DN; Hecht, DW; Johnson, S; Osmolski, JR; Sambol, SP1
Cloud, JW; Espinoza, D; Kelly, CP; Kokkotou, E; Michos, A; Moss, AC; Mustafa, N; O'Brien, M; Pothoulakis, C1
Finegold, SM; Molitoris, D; Väisänen, ML1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Botta, M; D'Agostino, I; De Luca, F; Del Prete, R; Deodato, D; Docquier, JD; Ferraro, T; Guglielmi, MB; Mancini, A; Pasero, C; Sannio, F; Truglio, GI; Visaggio, D; Visca, P; Zamperini, C1
Chen, J; Ding, C; Doyle, T; Duncan, L; Ebright, RH; He, S; Lin, W; Liu, Y; Lynch, AS; Ma, Z; Molodtsov, V; Nguyen, P; Pulse, M; Robertson, GT; Wang, H; Weiss, WJ; Xu, X; Yuan, Y; Zhuang, Z1

Reviews

1 review(s) available for vancomycin and rifaximin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for vancomycin and rifaximin

ArticleYear
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:8

    Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Humans; Microbial Sensitivity Tests; United States

2007
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:3

    Topics: Animals; Anti-Infective Agents; Clostridioides difficile; Cricetinae; Diarrhea; Enterocolitis, Pseudomembranous; Humans; Mesocricetus; Rifamycins; Rifaximin; Treatment Outcome; Vancomycin; Weight Gain

2008
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:1

    Topics: Ampicillin; Bacteria, Anaerobic; Feces; Microbial Sensitivity Tests; Neomycin; Nitro Compounds; Rifamycins; Rifaximin; Sulbactam; Teicoplanin; Thiazoles; Vancomycin

2009
Alkyl-guanidine Compounds as Potent Broad-Spectrum Antibacterial Agents: Chemical Library Extension and Biological Characterization.
    Journal of medicinal chemistry, 2018, 10-25, Volume: 61, Issue:20

    Topics: Alkylation; Anti-Bacterial Agents; Caco-2 Cells; Guanidine; Humans; Microbial Sensitivity Tests; Permeability; Structure-Activity Relationship

2018
Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens.
    Journal of medicinal chemistry, 2022, 03-24, Volume: 65, Issue:6

    Topics: Anaerobiosis; DNA-Directed RNA Polymerases; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Rifamycins

2022